BeiGene beigene.com


Public list: Pharma Startups (4733) Cancer Therapeutics (1133)

BeiGene is a Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that combines unique access to internal patient-derived biopsies with strong oncology biology. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collab...Show all

BeiGene is a Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that combines unique access to internal patient-derived biopsie...Show all

Company (IPO / Went public)

Phone: +86 10 58958000

Fax:

No.30 Science Park Road
Zhong-Guan-Cun Life Science Park
Beijing, 102 206
Beijing, China

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
BeiGene $335.4M Feb 3, 2016

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related BeiGene Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 8 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors Apr 28, 2017 Mar 20, 2018 Patent
Fused tricyclic compounds as raf kinase inhibitors Jan 22, 2016 Feb 20, 2018 Patent
Untitled Jun 11, 2015 Dec 05, 2017 Patent
Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones Jun 06, 2016 Nov 28, 2017 Patent
Fused tricyclic amide compounds as multiple kinase inhibitors Jun 27, 2014 Jun 06, 2017 Patent
See all 19 patents